![]() ![]() The RSB measure for morphine was 1.72 (3.86) (P < 0.05 vs. ![]() Effective analgesia was observed for all oliceridine regimens, with responder rates of 61.0%, 76.3%, and 70.0% for the 0.1-, 0.35-, and 0.5-mg regimens, respectively, compared with 45.7% for placebo (all P 0.05 vs. morphine.Ī total of 401 patients were treated with study medication. Secondary outcomes included a predefined composite measure of respiratory safety burden (RSB, representing the cumulative duration of respiratory safety events) and the proportion of treatment responders vs. The primary endpoint was the proportion of treatment responders over 24 hours for oliceridine regimens compared to placebo. Patients received a loading dose of either placebo, oliceridine (1.5 mg), or morphine (4 mg), followed by demand doses via patient-controlled analgesia (0.1, 0.35, or 0.5 mg oliceridine 1 mg morphine or placebo) with a 6-minute lockout interval. This phase III, double-blind, randomized trial (APOLLO-2 ) evaluated the efficacy and safety of oliceridine for acute pain following abdominoplasty. Oliceridine is a novel G protein-biased μ-opioid receptor agonist designed to provide analgesia with an improved safety and tolerability profile. The clinical utility of conventional IV opioids is limited by the occurrence of opioid-related adverse events. ![]()
0 Comments
Leave a Reply. |